Proteasome inhibition by bortezomib: Effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation

Transplant Immunology

Volumn 26, Issue 4, 2012, Pages 171-175

  Guthoff, Martina ^a   Schmid Horch, Barbara ^b   Weisel, Katja C ^c   Häring, Hans Ulrich ^a   Königsrainer, Alfred ^a,d   Heyne, Nils ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Institute of Clinical and Experimental Transfusion Medicine   (Germany)

^c Oncology and Immunology ^*  (Germany)

^d University of Tübingen ^*  (Germany)

Author keywords

Bortezomib; Desensitization; HLA antibodies; Kidney transplantation; Proteasome inhibition; Protective immunity

Indexed keywords

BORTEZOMIB; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; PROTEASOME;

ADULT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CASE REPORT; DESENSITIZATION; DRUG RESPONSE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INHIBITION KINETICS; KIDNEY HYPOPLASIA; KIDNEY TRANSPLANTATION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; SENSITIZATION;

EID: 84860437326     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.01.002     Document Type: Article

References (30)

1. Wolfe R.A., Ashby V.B., Milford E.L., Ojo A.O., Ettenger R.E., Agodoa L.Y., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730.
2. Vo A.A., Peng A., Toyoda M., Kahwaji J., Cao K., Lai C.H., et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010, 89:1095-1102.
3. Claas F.H., Rahmel A., Doxiadis I.I. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009, 88:447-452.
4. Jordan S.C., Peng A., Vo A.A. Therapeutic strategies in management of the highly HLA-sensitized and AB0-incompatible transplant recipients. Contrib Nephrol 2009, 162:13.
5. Doxiadis I.I., Claas F.H. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both. Curr Opin Organ Transplant 2009, 14:410.
6. Tyan D.B., Li V.A., Czer L., Trento A., Jordan S.C. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994, 57:553-562.
7. Montgomery R.A., Zachary A.A., Racusen L.C., Leffell M.S., King K.E., Burdick J., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch-positive recipients. Transplantation 2000, 70:887-895.
8. Stegall M.D., Gloor J.M. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010, 15:8-10.
9. Vo A.A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359:242-251.
10. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609.
11. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487.
12. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
13. Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
14. Voorhees P.M., Dees E.C., O'Neil B., Orlowski R.Z. The proteasome as a target for cancer therapy. Clin Cancer Res 2003, 9:6316-6325.
15. Perry D.K., Burns J.M., Pollinger H.S., Amiot B.P., Gloor J.M., Gores G.J., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
16. Neumann J., Tarrasconi H., Bortolotto A., Machuca T., Canabarro R., Sporleder H., et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation 2010, 89:125-126.
17. Everly M.J., Everly J.J., Susskind B., Brailey P., Arend L.J., Alloway R.R., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761.
18. Walsh R.C., Everly J.J., Brailey P., Rike A.H., Arend L.J., Mogilishetty G., et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010, 89:277-284.
19. Burns J.M., Cornell L.D., Perry D.K., Pollinger H.S., Gloor J.M., Kremers W.K., et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008, 8:2684-2694.
20. Idica A., Kaneku H., Everly M.J., Trivedi H.L., Feroz A., Vanikar A.V., et al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl 2008, 229-239.
21. Schnaidt M., Weinstock C., Jurisic M., Schmid-Horch B., Ender A., Wernet D. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation 2011, 92:510-515.
22. Vincenti F., Cohen S.D., Appel G. Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases. Clin J Am Soc Nephrol 2010, 5:142-151.
23. Cosio F.G., Gloor J.M., Sethi S., Stegall M.D. Transplant glomerulopathy. Am J Transplant 2008, 8:492-496.
24. Gloor J.M., Cosio F.G., Rea D.J., Wadei H.M., Winters J.L., Moore S.B., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006, 6:1841-1847.
25. Loupy A., Suberbielle-Boissel C., Hill G.S., Lefaucheur C., Anglicheau D., Zuber J., et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009, 9:2561-2570.
26. Sberro-Soussan R., Zuber J., Suberbielle-Boissel C., Candon S., Martinez F., Snanoudj R., et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010, 10:681-686.
27. Wahrmann M., Haidinger M., Körmöczi G.F., Weichhart T., Säemann M.D., Geyeregger R., et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010, 89:1385-1390.
28. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005, 106:2977-2981.
29. Everly M.J., Terasaki P.I., Hopfield J., Trivedi H.L., Kaneku H. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation 2010, 90:1493-1498.
30. Trivedi H.L., Terasaki P.I., Feroz A., Vanikar A.V., Trivedi V.B., Khemchandani S.I., et al. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation 2010, 90:221-222.